NEJM publishes POC data for Amgen mAb for asthma

The New England Journal of Medicine publishes the results from a 31-patient 12-week Phase 1 proof-of-concept study of Amgen's (AMGN +0.1%) AMG-157 mAb for asthma. The study's conclusion is that AMG-157 reduced allergen-induced bronchoconstriction and indexes of airway inflammation before and after allergen challenge. The results are statistically significant.

AMG-157 is a monoclonal immunoglobulin IgG2 that is a thymic stromal lymphopoietin (TSLP) inhibitor. TSLP is a cytokine thought to have a major role in allergic inflammation.

The product candidate is one of five mAbs from Amgen's inflammation portfolio that it is developing with AstraZeneca (AZN +2.2%).

From other sites
Comments (2)
  • Howard Hunt
    , contributor
    Comments (105) | Send Message
    Is this really significant for either company?
    20 May 2014, 05:04 PM Reply Like
  • Dr Joseph Haluska
    , contributor
    Comments (499) | Send Message
    I'm not an expert on this, but considering 3,300 annual asthma deaths in the U.S. and 250,000 worldwide annual deaths, $56 billion spent annually on its treatment, I would think there's significance. Not to mention the foothold into cytokine research this represents. Oh, and considering the misery of 25 million American asthmatics, 150 million worldwide, living on bronchodilators and steroids.......
    I'd say.
    long AMGN, AZN
    20 May 2014, 06:27 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs